These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
372 related articles for article (PubMed ID: 18228186)
1. Myodys, a full-length dystrophin plasmid vector for Duchenne and Becker muscular dystrophy gene therapy. Duan D Curr Opin Mol Ther; 2008 Feb; 10(1):86-94. PubMed ID: 18228186 [TBL] [Abstract][Full Text] [Related]
2. Design of trans-splicing adeno-associated viral vectors for Duchenne muscular dystrophy gene therapy. Lai Y; Li D; Yue Y; Duan D Methods Mol Biol; 2008; 433():259-75. PubMed ID: 18679629 [TBL] [Abstract][Full Text] [Related]
3. The future of Duchenne muscular dystrophy gene therapy: shrinking the dystrophin gene. Roberts M; Dickson G Curr Opin Mol Ther; 2002 Aug; 4(4):343-8. PubMed ID: 12222872 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic strategies for Duchenne and Becker dystrophies. Voisin V; de la Porte S Int Rev Cytol; 2004; 240():1-30. PubMed ID: 15548414 [TBL] [Abstract][Full Text] [Related]
9. Efficient and fast functional screening of microdystrophin constructs in vivo and in vitro for therapy of duchenne muscular dystrophy. Jørgensen LH; Larochelle N; Orlopp K; Dunant P; Dudley RW; Stucka R; Thirion C; Walter MC; Laval SH; Lochmüller H Hum Gene Ther; 2009 Jun; 20(6):641-50. PubMed ID: 19239382 [TBL] [Abstract][Full Text] [Related]
10. Naked plasmid DNA for the treatment of muscular dystrophy. Braun S Curr Opin Mol Ther; 2004 Oct; 6(5):499-505. PubMed ID: 15537051 [TBL] [Abstract][Full Text] [Related]
11. Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD). Athanasopoulos T; Graham IR; Foster H; Dickson G Gene Ther; 2004 Oct; 11 Suppl 1():S109-21. PubMed ID: 15454965 [TBL] [Abstract][Full Text] [Related]
13. [Construction of recombinant plasmid pVAX1-microdystrophin and preliminary study on the treatment to Duchenne muscular dystrophy]. Xiong F; Zhang C; Zheng H; Xiao S; Yu M; Xu Y; Liu Z; Zhou C Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Dec; 25(6):624-8. PubMed ID: 19065517 [TBL] [Abstract][Full Text] [Related]
14. Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies. Part II: clinical protocol. Romero NB; Benveniste O; Payan C; Braun S; Squiban P; Herson S; Fardeau M Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S45-8. PubMed ID: 12206794 [TBL] [Abstract][Full Text] [Related]
19. Gene therapy: the 'pro-sense' approach to Duchenne muscular dystrophy. van Deutekom JC Eur J Hum Genet; 2005 May; 13(5):518-9. PubMed ID: 15714219 [No Abstract] [Full Text] [Related]
20. Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies. Part III. Ethical considerations. Fardeau M Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S52-4. PubMed ID: 12206796 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]